Skip to main content

Table 3 Risk factors correlated with cancer-specific survival in all appendiceal cancer patients

From: Chemotherapy in the treatment of different histological types of appendiceal cancers: a SEER based study

Variable

Cancer-specific Survival

Overall survival

 

Univariate

P value

Multivariate

P value

Univariate

P value

Multivariate

P value

 

HR (95% CI)

 

HR (95% CI)

 

HR (95% CI)

 

HR (95% CI)

 

Age

  ≤ 56

1

 

1

 

1

 

1

 

  > 56

1.46 (1.3–1.64)

<.0001

1.19 (1.05–1.34)

0.0054

1.99 (1.8–2.19)

<.0001

1.61 (1.45–1.78)

<.0001

Gender

 Male

1

   

1

 

1

 

 Female

1.06 (0.94–1.19)

0.3459

  

0.92 (0.84–1.01)

0.0715

0.82 (0.74–0.9)

<.0001

Marital status

 Married

1

 

1

 

1

 

1

 

 Unmarrieda

1.04 (0.92–1.18)

0.507

1.24 (1.09–1.4)

0.0008

1.17 (1.07–1.29)

0.0011

1.35 (1.22–1.49)

<.0001

 Unknown

0.78 (0.58–1.06)

0.1106

1.3 (0.96–1.77)

0.092

0.84 (0.66–1.07)

0.1632

1.28 (1–1.63)

0.0501

Race

 African American

1

 

1

 

1

 

1

 

 White

0.72 (0.6–0.85)

0.0002

0.75 (0.62–0.9)

0.0017

0.75 (0.65–0.86)

<.0001

0.82 (0.71–0.95)

0.0068

 Other

0.9 (0.69–1.18)

0.447

0.77 (0.58–1.02)

0.0728

0.82 (0.65–1.02)

0.0744

0.8 (0.63–1.02)

0.0657

 Unknown

0.16 (0.04–0.64)

0.0098

0.39 (0.1–1.6)

0.1928

0.16 (0.05–0.49)

0.0014

0.33 (0.11–1.04)

0.0592

Region

 West

1

 

1

 

1

 

1

 

 South

1.16 (1.01–1.34)

0.0397

1.22 (1.05–1.42)

0.01

1.16 (1.03–1.3)

0.0124

1.2 (1.06–1.35)

0.0034

 Midwest

1.38 (1.14–1.67)

0.0008

1.22 (1–1.49)

0.0478

1.29 (1.1–1.51)

0.0014

1.18 (1–1.39)

0.0475

 Northwest

0.93 (0.79–1.1)

0.3925

1.03 (0.87–1.21)

0.7785

0.98 (0.86–1.12)

0.7558

1.06 (0.93–1.21)

0.3898

CEA

 Negative

1

 

1

 

1

 

1

 

 Positive

1.82 (1.54–2.15)

<.0001

1.4 (1.17–1.67)

0.0006

1.67 (1.45–1.93)

<.0001

1.33 (1.14–1.54)

0.0002

 Unknown

0.53 (0.45–0.61)

<.0001

0.97 (0.83–1.14)

0.7777

0.63 (0.55–0.71)

<.0001

0.99 (0.87–1.13)

0.909

Deposit

 Negative

1

 

1

 

1

 

1

 

 Positive

4.21 (3.49–5.07)

<.0001

1.31 (1.07–1.6)

0.008

3.36 (2.88–3.92)

<.0001

1.36 (1.15–1.61)

0.0003

 Unknown

1.15 (1–1.32)

0.0431

1.37 (1.19–1.58)

<.0001

1.04 (0.93–1.16)

0.4885

1.22 (1.09–1.37)

0.0007

Tumor size

  < 2 cm

1

 

1

 

1

 

1

 

 2–2.9 cm

3.45 (2.64–4.5)

<.0001

1.23 (0.93–1.62)

0.1461

2.18 (1.8–2.65)

<.0001

1.12 (0.91–1.38)

0.2898

  ≤ 3 cm

5.2 (4.2–6.42)

<.0001

1.33 (1.06–1.67)

0.0143

3.19 (2.76–3.69)

<.0001

1.25 (1.06–1.47)

0.0085

 Unknown

4.53 (3.64–5.65)

<.0001

1.33 (1.06–1.69)

0.0163

2.87 (2.46–3.34)

<.0001

1.24 (1.05–1.47)

0.0132

Harvested lymph nodes

  ≤ 12

1

 

1

 

1

 

1

 

  > 12

0.88 (0.78–0.99)

0.0318

0.58 (0.51–0.66)

<.0001

0.82 (0.75–0.91)

<.0001

0.61 (0.55–0.68)

<.0001

 Unknown

1.76 (1.14–2.72)

0.0108

0.85 (0.55–1.32)

0.5551

1.46 (1–2.12)

0.0501

0.82 (0.56–1.2)

0.2969

Histology

 GCC

1

 

1

 

1

 

1

 

 MAC

2.39 (1.85–3.09)

<.0001

1.31 (0.99–1.74)

0.0609

1.81 (1.5–2.19)

<.0001

1.16 (0.94–1.43)

0.1765

 NMAC

3.59 (2.77–4.67)

<.0001

2.26 (1.71–2.99)

<.0001

2.91 (2.4–3.53)

<.0001

2.05 (1.66–2.53)

<.0001

 SRCC

6.81 (5.16–8.99)

<.0001

1.89 (1.4–2.55)

<.0001

4.63 (3.75–5.71)

<.0001

1.78 (1.41–2.24)

<.0001

 NECs

0.42 (0.23–0.74)

0.0027

0.76 (0.42–1.4)

0.3776

0.63 (0.44–0.89)

0.0093

0.95 (0.65–1.39)

0.7755

 NETs

0.12 (0.06–0.23)

<.0001

0.32 (0.16–0.65)

0.0017

0.35 (0.26–0.48)

<.0001

0.64 (0.45–0.92)

0.0171

 MiNENs

3.03 (2.18–4.2)

<.0001

1.72 (1.23–2.41)

0.0016

2.08 (1.61–2.7)

<.0001

1.4 (1.07–1.83)

0.0137

T stage

 T1

1

 

1

 

1

 

1

 

 T2

1.54 (0.96–2.46)

0.0741

0.77 (0.47–1.24)

0.2788

1.34 (1.03–1.76)

0.0327

0.79 (0.59–1.05)

0.1077

 T3

4.51 (3.32–6.13)

<.0001

1.51 (1.08–2.12)

0.0165

2.38 (1.99–2.85)

<.0001

1.15 (0.93–1.43)

0.1923

 T4

12.72 (9.5–17.02)

<.0001

2.38 (1.71–3.32)

<.0001

5.2 (4.4–6.15)

<.0001

1.69 (1.37–2.09)

<.0001

N stage

 N0

1

 

1

 

1

 

1

 

 N1

3.14 (2.72–3.62)

<.0001

2.26 (1.93–2.65)

<.0001

2.32 (2.06–2.61)

<.0001

2 (1.75–2.28)

<.0001

 N2

8.15 (7.05–9.42)

<.0001

3.03 (2.53–3.62)

<.0001

5.8 (5.14–6.56)

<.0001

2.89 (2.48–3.37)

<.0001

M stage

 M0

1

 

1

 

1

 

1

 

 M1

5.46 (4.85–6.16)

<.0001

2.45 (2.1–2.86)

<.0001

3.47 (3.16–3.81)

<.0001

2.04 (1.8–2.31)

<.0001

Grade

 Well differentiated

1

 

1

 

1

 

1

 

 Moderately differentiated

2.83 (2.33–3.44)

<.0001

1.62 (1.32–1.99)

<.0001

2.32 (2.01–2.67)

<.0001

1.49 (1.28–1.73)

<.0001

 Poorly or un-differentiated

8.52 (7.08–10.26)

<.0001

2.73 (2.2–3.39)

<.0001

5.44 (4.73–6.25)

<.0001

2.21 (1.87–2.62)

<.0001

 Unknown

2.53 (2.05–3.11)

<.0001

2.16 (1.73–2.69)

<.0001

2.08 (1.78–2.42)

<.0001

1.71 (1.45–2.02)

<.0001

Surgery

 Less than hemicolectomy

1

   

1

 

1

 

 Hemicolectomy or more

1.43 (1.26–1.63)

<.0001

  

1.22 (1.11–1.35)

<.0001

0.89 (0.8–0.98)

0.024

 Other

2.88 (2.36–3.52)

<.0001

  

2.16 (1.82–2.56)

<.0001

1.51 (1.26–1.81)

<.0001

Chemotherapy

 No

1

 

1

 

1

 

1

 

 Yes

3.54 (3.14–3.99)

<.0001

0.93 (0.8–1.07)

0.2983

2.11 (1.93–2.32)

<.0001

0.73 (0.65–0.82)

<.0001

  1. aUnmarried status including divorced, separated, widowed and unmarried. CI confidence interval; HR hazard ratio; SRCC signet ring cell carcinoma; MAC mucinous adenocarcinomas; NMAC non-mucinous adenocarcinoma; MiNENs mixed neuroendocrine non-neuroendocrine neoplasms; GCC goblet cell carcinoma; NETs neuroendocrine tumors; NECs neuroendocrine carcinomas